CLEVIPREX® (clevidipine) pharmacology and mechanism of action
CLEVIPREX rapidly lowers arterial blood pressure
Titratable, fast onset of action1
CLEVIPREX begins to reduce SBP within 2 minutes of initiation dose. An approximately 1–2 mg/hr increase will generally produce an additional 2–4 mmHg decrease in systolic pressure.
CLEVIPREX has a half-life of ~1 minute. In most patients, full recovery of BP is achieved 5–15 minutes after the infusion is stopped.
The pharmacology of CLEVIPREX1
CLEVIPREX is titrated to the desired reduction in BP. The effect of CLEVIPREX appears to plateau at approximately 25% of baseline systolic pressure. The infusion rate for which half the maximal effect is observed is approximately 10 mg/hr.
Mechanism of action1
CLEVIPREX works by selectively dilating arterial smooth muscle via calcium channel blockade, reducing systemic vascular resistance without affecting preload.
Dr. Horowitz speaks about CLEVIPREX
Renowned anesthesiologist Dr. Todd Horowitz discusses CLEVIPREX clinical trial results and dosing in a series of informative videos for healthcare professionals.
Individualized, titratable administration1
CLEVIPREX offers low-volume, non–weight-based dosing that is independent of renal or hepatic function.
CLEVIPREX has been recommended in the AHA/ASA Acute Ischemic Stroke Guidelines since 20182
Proven efficacy in clinical studies1,3-6
CLEVIPREX provided blood pressure reduction in a range of patients and various clinical settings.